ICIs have been widely used for non-small cell lung cancer (NSCLC) following the demonstration of significant anti-tumor activity with anti-PD-(L)1 therapy in metastatic patients [2–6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.